<DOC>
	<DOCNO>NCT01133431</DOCNO>
	<brief_summary>To assess pharmacokinetic Interaction CKD-501 sulfonylurea ( Glimepiride ) healthy male subject .</brief_summary>
	<brief_title>The Pharmacokinetic Interaction Between CKD-501 Sulfonylurea</brief_title>
	<detailed_description />
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Healthy male adult age 20 45 screening period Weight 45kg within Â±20 % range Ideal Boby Weight Agreement write informed consent Subject sign symptom acute disease within 28 day start administration investigational drug Subject history ( inflammatory gastrointestinal disease , gastric duodenal ulcer , liver disease , gastrointestinal surgical history except appendectomy ) affect ADME drug Clinically significant , active gastrointestinal system , cardiovascular system , pulmonary system , renal system , endocrine system , blood system , digestive system , central nervous system , mental disease malignancy Inadequate subject medical examination ( medical history , physical examination , ECG , laboratory test ) within 28 day start administration investigational drug Inadequate laboratory test result AST ( SGOT ) ALT ( SGPT ) &gt; 1.25 x upper limit normal range Total bilirubin &gt; 1.5 x upper limit normal range Clinically significant allergic disease ( except mild allergic rhinitis need medication ) Subject know hypersensitivity reaction glitazones sulfonylureas Previously participate trial within 60 day Medication drugmediated induction/inhibition metabolic enzyme barbiturate within 1 month may affect clinical trial within 10 day Subject take abnormal meal affect ADME drug Impossible take institutional standard meal Previously donate whole blood within 60 day component blood within 20 day Continued take caffeine ( caffeine &gt; 5 cup/day ) , drink ( alcohol &gt; 30 g/day ) stop drinking severe heavy smoker ( cigarette &gt; 10 cigarette per day ) clinical trial An impossible one participate clinical trial investigator 's decision include laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>CKD-501</keyword>
	<keyword>Glimepiride</keyword>
	<keyword>Placebo</keyword>
	<keyword>Healthy male volunteer</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Metabolite</keyword>
</DOC>